Developer docs
API playgroundTry for free, no card

Search company profiles

ChronicleBio

Full company profile

uuid00esdn4

Namestring
ChronicleBio
Legal namestring
ChronicleBio
Company typeenum
Private
Founded yearint
2025
Descriptiontext

ChronicleBio is a privately held techbio startup founded in 2025 and headquartered in the San Francisco Bay Area (Menlo Park), building an AI-driven multi-omic data platform aimed at accelerating diagnosis and treatment for complex neuroimmune disorders including ME/CFS, Long COVID, POTS, migraine, MCAS, Ehlers-Danlos Syndrome, Sjögren's, persistent Lyme, and fibromyalgia. The company's core technology is a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to stratify patients by disease mechanism before treatment begins, addressing the systemic failure of chronic disease drug pipelines that historically lack mechanism-anchored patient selection. The platform is fed by the Chronicle I Study and Chronicle Connect participant app, which collect longitudinal clinical data, wearable telemetry, symptom logs, and biospecimens (blood, urine, cheek swab) through a four-clinic partner network in Texas and Utah, supplemented by access to the Solve M.E. Solve Together dataset (the largest ME/CFS/Long COVID patient-reported dataset in the U.S.) via a five-party research consortium with Solve M.E., the Brain Inflammation Collaborative, the Complex Disorders Alliance, and CareEvolution.

The intended revenue model combines biopharmaceutical development (biomarker discovery, patient stratification, and precision therapeutic development for licensing or royalty economics) with data and research services to pharmaceutical companies, biotech firms, and research organizations. Leadership combines commercial-tech and biomedical depth: Co-Founder & CEO Rohit Gupta (formerly Stanford and UCSF biobanking), Co-Founder & Director Fidji Simo (Instacart CEO, incoming CEO of OpenAI's applications division), Co-Founder & Executive Chairman Rishi Reddy (Tarsadia Investments), CSO Dr. John Mumm (founder of Deka Biosciences, founding member of ARMO BioSciences acquired by Eli Lilly for $1.6B), and Head of Platform Dr. Yambazi Banda (Oxford Rhodes Scholar, former UCSF and Ancestry.com genomics leader). The company is sub-50 employees, venture-backed by Wisdom Ventures, and is at platform-buildout and data-acquisition stage rather than commercial revenue.

Short descriptiontext

ChronicleBio is a venture-backed techbio startup building an AI-driven multi-omic data platform to stratify patients with complex neuroimmune disorders (ME/CFS, Long COVID, POTS) by disease mechanism, supporting biomarker discovery, drug repurposing, and precision therapeutic development for biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omics data platform, biomarker discovery, patient stratification, precision medicine, drug repurposing
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Precision Medicine Data Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical Development
TypeLicensing Royalties
Description

ChronicleBio is developing therapeutics through biomarker discovery, patient stratification, and precision therapeutic development for neuroimmune conditions. The company applies patient data to fuel transformative clinical trials and identify which clinical-stage drugs might work for specific patient subgroups.

chroniclebio.com
2Data & Research Services
TypeProfessional Services
Description

The company provides data services to research partners, pharmaceutical companies, and healthcare organizations through its multi-omic analysis platform, biomarker discovery capabilities, and patient stratification insights.

chroniclebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Chronicle I
Description

A research study part of Chronicle Connect, where participants contribute health data, biospecimens, and lived experience to accelerate breakthroughs for complex chronic conditions including ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, and Fibromyalgia.

chroniclebio.com
Core offering1 text field

ChronicleBio builds a multi-omic endotype framework integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment. The company combines clinical and biological data, large biological models trained on native human biology, and longitudinal multimodal patient data into an 'Internet of Biology' data ecosystem to power biomarker discovery, drug repurposing, and new diagnostics for complex neuroimmune conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Potential to transform 20% response rates into 70% response rates with right biomarker stratification
Product overview1 text field

ChronicleBio is a data-driven techbio company building the 'Internet of Biology' — a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics data to stratify patients by disease mechanism before treatment begins. The core Multi-Omic Endotype Framework powers biomarker discovery, drug repurposing, and new diagnostics. The Chronicle I Study serves as the primary data collection vehicle, sourcing rich longitudinal multimodal clinical and biological data through the Chronicle Connect participant platform, creating an interconnected data ecosystem that trains AI models on native human biology to unlock novel therapeutic insights for neuroimmune conditions.

Product and service1 record
1Chronicle I Study
CategoryClinical Research Study
Description

A research study enrolling patients with complex chronic conditions (ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, Fibromyalgia) to contribute health data, biospecimens, and lived experience that power biomarker discovery, drug repurposing, and new diagnostics.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-27
Description

Solve M.E., a national nonprofit dedicated to making ME/CFS, Long COVID, and IACCIs widely understood, diagnosable, and treatable, has collected patient-reported data through the Solve Together platform since 2010. This partnership allows ChronicleBio to receive patient data to deepen insights and fuel transformative clinical trials. The Solve Together platform is the largest database of its kind in the U.S. and contains pre- and post-COVID-19 health information.

2Brain Inflammation Collaborative (BIC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-27
Description

The Brain Inflammation Collaborative, a patient-centered nonprofit, took over management of the Solve Together platform and will expand it to include pediatric populations, additional diagnoses, and assessments on links between brain inflammation and mental health. The goal is more diverse and inclusive research across rural, marginalized, and underserved communities.

chroniclebio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-27
Description

The Complex Disorders Alliance, a patient-founded nonprofit that drives the development of diagnostics and treatments, receives data from Solve M.E. as part of the collaboration. The partnership aims to unite, pool data, insights, and expertise to drive breakthroughs that put patients first.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-27
Description

CareEvolution created the Solve Together dynamic platform that allows users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies. The platform serves as the technical backbone for the research collaboration and is the largest database of its kind in the U.S.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner clinic for biobank sample collection including blood, urine, or cheek swab. The partnership enables ChronicleBio to source biospecimens for its multi-omics analysis platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner clinic for biobank sample collection and clinical research coordination. The center is dedicated to improving care for patients with complex chronic conditions.

7FourPeaks Health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner clinic for biobank sample collection and clinical research coordination. Serves as a clinical site for ChronicleBio's research activities.

chroniclebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner clinic for biobank sample collection and clinical research coordination. Specialized clinic supporting ChronicleBio's participant engagement efforts.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology and multi-omic data to identify therapeutic targets, closely aligned with ChronicleBio's AI-on-native-biology approach.

TypeDirect peer
Description

Biomedical AI company that builds multi-omic patient stratification models and partners with pharma to accelerate drug development, sharing the 'AI + multi-omics + pharma BD' model.

3Tempus AI
TypeBroad incumbent
Description

Established multi-omic data platform and AI company serving oncology and increasingly other disease areas; a broader incumbent operating at scale with pharma partnerships that ChronicleBio aspires to compete with.

TypeOthers
Description

Health data platform that powers the Solve Together infrastructure ChronicleBio now uses; relevant as the enabling technology partner and adjacent ecosystem participant.

TypeBroad incumbent
Description

Genomic profiling leader (now owned by Roche) that pioneered biomarker-driven treatment selection via large-scale molecular data; represents the gold standard for multi-omic-to-treatment pipelines ChronicleBio seeks to replicate in neuroimmune indications.

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology with foundation models; a larger and more mature comparable in the techbio category, though with broader indication scope.

TypeOthers
Description

Patient-driven health data platform with deep roots in chronic disease communities; comparable for its community-led approach to generating longitudinal patient-reported data, a model ChronicleBio adapts for the multi-omic era.

TypeBroad incumbent
Description

Generative AI biology company building foundation models on biological data to design novel therapeutics, comparable in its AI-on-biology orientation though with a different downstream product strategy.

9nference
TypeDirect peer
Description

Biomedical AI platform that synthesizes multi-omic and clinical data to surface therapeutic insights and accelerate pharma R&D, a directly comparable multi-omic AI platform serving pharma partners.

TypeDirect peer
Description

Network-medicine platform using molecular data and AI to match patients with effective therapies for complex autoimmune and inflammatory diseases, directly comparable to ChronicleBio's multi-omic stratification thesis for complex conditions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChronicleBio

Precision Medicine Data Platformchroniclebio.com

ChronicleBio is a venture-backed techbio startup building an AI-driven multi-omic data platform to stratify patients with complex neuroimmune disorders (ME/CFS, Long COVID, POTS) by disease mechanism, supporting biomarker discovery, drug repurposing, and precision therapeutic development for biopharma partners.

What ChronicleBio does

ChronicleBio is a privately held techbio startup founded in 2025 and headquartered in the San Francisco Bay Area (Menlo Park), building an AI-driven multi-omic data platform aimed at accelerating diagnosis and treatment for complex neuroimmune disorders including ME/CFS, Long COVID, POTS, migraine, MCAS, Ehlers-Danlos Syndrome, Sjögren's, persistent Lyme, and fibromyalgia. The company's core technology is a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to stratify patients by disease mechanism before treatment begins, addressing the systemic failure of chronic disease drug pipelines that historically lack mechanism-anchored patient selection. The platform is fed by the Chronicle I Study and Chronicle Connect participant app, which collect longitudinal clinical data, wearable telemetry, symptom logs, and biospecimens (blood, urine, cheek swab) through a four-clinic partner network in Texas and Utah, supplemented by access to the Solve M.E. Solve Together dataset (the largest ME/CFS/Long COVID patient-reported dataset in the U.S.) via a five-party research consortium with Solve M.E., the Brain Inflammation Collaborative, the Complex Disorders Alliance, and CareEvolution.

The intended revenue model combines biopharmaceutical development (biomarker discovery, patient stratification, and precision therapeutic development for licensing or royalty economics) with data and research services to pharmaceutical companies, biotech firms, and research organizations. Leadership combines commercial-tech and biomedical depth: Co-Founder & CEO Rohit Gupta (formerly Stanford and UCSF biobanking), Co-Founder & Director Fidji Simo (Instacart CEO, incoming CEO of OpenAI's applications division), Co-Founder & Executive Chairman Rishi Reddy (Tarsadia Investments), CSO Dr. John Mumm (founder of Deka Biosciences, founding member of ARMO BioSciences acquired by Eli Lilly for $1.6B), and Head of Platform Dr. Yambazi Banda (Oxford Rhodes Scholar, former UCSF and Ancestry.com genomics leader). The company is sub-50 employees, venture-backed by Wisdom Ventures, and is at platform-buildout and data-acquisition stage rather than commercial revenue.

ChronicleBio firmographics

Firmographics
Name
ChronicleBio
Legal name
ChronicleBio
Website
https://chroniclebio.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
ChronicleBio is a venture-backed techbio startup building an AI-driven multi-omic data platform to stratify patients with complex neuroimmune disorders (ME/CFS, Long COVID, POTS) by disease mechanism, supporting biomarker discovery, drug repurposing, and precision therapeutic development for biopharma partners.
Ownership category
akta.pro rank

ChronicleBio industry classification

Industry
Product category
Precision Medicine Data Platform
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Multi-omics data platform
  • Biomarker discovery
  • Patient stratification
  • Precision medicine
  • Drug repurposing

Where ChronicleBio is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ChronicleBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development: ChronicleBio is developing therapeutics through biomarker discovery, patient stratification, and precision therapeutic development for neuroimmune conditions. The company applies patient data to fuel transformative clinical trials and identify which clinical-stage drugs might work for specific patient subgroups.
  2. Data & Research Services: The company provides data services to research partners, pharmaceutical companies, and healthcare organizations through its multi-omic analysis platform, biomarker discovery capabilities, and patient stratification insights.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

ChronicleBio product offering

Product offering

Core offering

ChronicleBio builds a multi-omic endotype framework integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment. The company combines clinical and biological data, large biological models trained on native human biology, and longitudinal multimodal patient data into an 'Internet of Biology' data ecosystem to power biomarker discovery, drug repurposing, and new diagnostics for complex neuroimmune conditions.

Product overview

ChronicleBio is a data-driven techbio company building the 'Internet of Biology' — a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics data to stratify patients by disease mechanism before treatment begins. The core Multi-Omic Endotype Framework powers biomarker discovery, drug repurposing, and new diagnostics. The Chronicle I Study serves as the primary data collection vehicle, sourcing rich longitudinal multimodal clinical and biological data through the Chronicle Connect participant platform, creating an interconnected data ecosystem that trains AI models on native human biology to unlock novel therapeutic insights for neuroimmune conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Chronicle I: A research study part of Chronicle Connect, where participants contribute health data, biospecimens, and lived experience to accelerate breakthroughs for complex chronic conditions including ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, and Fibromyalgia.

Products and services

  • Chronicle I Study A research study enrolling patients with complex chronic conditions (ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, Fibromyalgia) to contribute health data, biospecimens, and lived experience that power biomarker discovery, drug repurposing, and new diagnostics.

Quantifiable outcome

  • Potential to transform 20% response rates into 70% response rates with right biomarker stratification

Companies that use ChronicleBio

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

ChronicleBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

ChronicleBio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Solve M.E.coreStrategic or Co-development Partner · 27 June 2025Solve M.E., a national nonprofit dedicated to making ME/CFS, Long COVID, and IACCIs widely understood, diagnosable, and treatable, has collected patient-reported data through the Solve Together platform since 2010. This partnership allows ChronicleBio to receive patient data to deepen insights and fuel transformative clinical trials. The Solve Together platform is the largest database of its kind in the U.S. and contains pre- and post-COVID-19 health information.
  • Brain Inflammation Collaborative (BIC)coreStrategic or Co-development Partner · 27 June 2025The Brain Inflammation Collaborative, a patient-centered nonprofit, took over management of the Solve Together platform and will expand it to include pediatric populations, additional diagnoses, and assessments on links between brain inflammation and mental health. The goal is more diverse and inclusive research across rural, marginalized, and underserved communities.
  • Complex Disorders AlliancecoreStrategic or Co-development Partner · 27 June 2025The Complex Disorders Alliance, a patient-founded nonprofit that drives the development of diagnostics and treatments, receives data from Solve M.E. as part of the collaboration. The partnership aims to unite, pool data, insights, and expertise to drive breakthroughs that put patients first.
  • CareEvolutioncoreTechnology or Integration · 27 June 2025CareEvolution created the Solve Together dynamic platform that allows users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies. The platform serves as the technical backbone for the research collaboration and is the largest database of its kind in the U.S.
  • Continental HospitalscoreStrategic or Co-development PartnerPartner clinic for biobank sample collection including blood, urine, or cheek swab. The partnership enables ChronicleBio to source biospecimens for its multi-omics analysis platform.
  • Bateman Horne CentercoreStrategic or Co-development PartnerPartner clinic for biobank sample collection and clinical research coordination. The center is dedicated to improving care for patients with complex chronic conditions.
  • FourPeaks HealthcoreStrategic or Co-development PartnerPartner clinic for biobank sample collection and clinical research coordination. Serves as a clinical site for ChronicleBio's research activities.
  • The Heartbeat ClinicscoreStrategic or Co-development PartnerPartner clinic for biobank sample collection and clinical research coordination. Specialized clinic supporting ChronicleBio's participant engagement efforts.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

ChronicleBio competitors and assessment

Company assessment

Direct peers

  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology and multi-omic data to identify therapeutic targets, closely aligned with ChronicleBio's AI-on-native-biology approach.
  • Owkin: Biomedical AI company that builds multi-omic patient stratification models and partners with pharma to accelerate drug development, sharing the 'AI + multi-omics + pharma BD' model.
  • nference: Biomedical AI platform that synthesizes multi-omic and clinical data to surface therapeutic insights and accelerate pharma R&D, a directly comparable multi-omic AI platform serving pharma partners.
  • Scipher Medicine: Network-medicine platform using molecular data and AI to match patients with effective therapies for complex autoimmune and inflammatory diseases, directly comparable to ChronicleBio's multi-omic stratification thesis for complex conditions.

Broad incumbents

  • Tempus AI: Established multi-omic data platform and AI company serving oncology and increasingly other disease areas; a broader incumbent operating at scale with pharma partnerships that ChronicleBio aspires to compete with.
  • Foundation Medicine (Roche): Genomic profiling leader (now owned by Roche) that pioneered biomarker-driven treatment selection via large-scale molecular data; represents the gold standard for multi-omic-to-treatment pipelines ChronicleBio seeks to replicate in neuroimmune indications.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with foundation models; a larger and more mature comparable in the techbio category, though with broader indication scope.
  • Generate:Biomedicines: Generative AI biology company building foundation models on biological data to design novel therapeutics, comparable in its AI-on-biology orientation though with a different downstream product strategy.

Others

  • CareEvolution: Health data platform that powers the Solve Together infrastructure ChronicleBio now uses; relevant as the enabling technology partner and adjacent ecosystem participant.
  • PatientsLikeMe: Patient-driven health data platform with deep roots in chronic disease communities; comparable for its community-led approach to generating longitudinal patient-reported data, a model ChronicleBio adapts for the multi-omic era.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

ChronicleBio social profiles

Digital presence

ChronicleBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChronicleBio leadership team

Management profile

Number of profiles

Profiles6 records

ChronicleBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChronicleBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChronicleBio

What does ChronicleBio do?

ChronicleBio builds a multi-omic endotype framework integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment. The company combines clinical and biological data, large biological models trained on native human biology, and longitudinal multimodal patient data into an 'Internet of Biology' data ecosystem to power biomarker discovery, drug repurposing, and new diagnostics for complex neuroimmune conditions.

Is ChronicleBio a public or private company?

ChronicleBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was ChronicleBio founded?

ChronicleBio was founded in 2025. It employs 11 to 50 people.

Where is ChronicleBio based?

ChronicleBio is headquartered in Menlo Park, United States, in the North America region.

How does ChronicleBio make money?

Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are data & Research Services.

Who are ChronicleBio's main competitors?

Direct peers on record are Insitro, Owkin, nference and Scipher Medicine. Broad incumbents are Tempus AI, Foundation Medicine (Roche), Recursion Pharmaceuticals and Generate:Biomedicines. Others are CareEvolution and PatientsLikeMe.

Does ChronicleBio have an API?

No public API is recorded for ChronicleBio.

What industry is ChronicleBio in?

ChronicleBio's product category is Precision Medicine Data Platform. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogChronicleBio and Prolong Pharmaceuticals Announce Partnership to Evaluate PP-007 in Myalgic Encephalomyelitis/Chronic Fatigue SyndromeChronicleBio and Prolong Pharmaceuticals announced a development agreement to evaluate PP-007, an oxygen-delivery therapy, for post-exertional malaise in ME/CFS. A planned Phase 2a trial will enroll at least 40 patients, with first dosing anticipated mid-2027. The study will use ChronicleBio's AI platform to identify patients most likely to respond.Inc.A Former Instacart CEO Can’t Stand for More Than 10 Minutes—She’s Building a Company to Find a CureFidji Simo, former OpenAI and Instacart CEO, co-founded ChronicleBio to use AI and a biobank to find treatments for POTS, long COVID, and chronic illness. She said she cannot stand or sit for more than five to ten minutes without passing out. The company has raised over $20 million from investors including Patrick Collison.ForbesFormer OpenAI Exec Fidji Simo’s $20 Million Plan To Solve Her Chronic Disease And OthersFidji Simo, former OpenAI exec, co-founded ChronicleBio to study chronic conditions like POTS and ME/CFS. The company raised $20 million and has identified 13 subtypes across these illnesses. It plans first trials in ME/CFS this year.WebProNewsFidji Simo and Dario Amodei Clash on AI’s Path to Curing DiseaseFormer OpenAI executive Fidji Simo and Anthropic CEO Dario Amodei are engaged in a public debate regarding the timeline and feasibility of using AI to cure diseases, with Simo emphasizing the critical need for biological data infrastructure over model intelligence alone. Simo's startup, ChronicleBio, is actively collecting high-quality biological data from patients with chronic conditions to support this effort, while critics question Amodei's optimistic five-to-ten-year timeline as unrealistic given current regulatory and scientific hurdles.The Times of IndiaOpenAI's former top exec Fidji Simo admits that she disagrees with Dario Amodei on most things, but says he is spot on treatment of ...OpenAI cofounder Fidji Simo publicly endorsed Anthropic CEO Dario Amodei’s argument that the AI industry must deliver concrete medical breakthroughs, such as curing cancer, to regain public trust. Simo emphasized that overcoming biological data infrastructure gaps is a critical bottleneck for applying AI to complex chronic diseases. She highlighted her startup ChronicleBio's mission to build necessary datasets for conditions lacking robust research history.Business InsiderFidji Simo says she believes AI can 'cure all diseases,' agreeing with Anthropic CEO Dario AmodeiFormer OpenAI executive and ChronicleBio cofounder Fidji Simo agreed with Anthropic CEO Dario Amodei that AI companies must deliver concrete medical breakthroughs rather than relying on sweeping promises. Simo emphasized that curing diseases requires not just intelligent models but also the necessary biological data infrastructure, noting that cancer research is uniquely positioned for progress due to existing datasets. She stated that AI can potentially cure all diseases only if biological infrastructure scales alongside model improvements.AijournChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted TherapeuticsChronicleBio appointed Dr. John Mumm, a three-decade immunology innovator and serial founder, as Chief Scientific Officer alongside Head of Platform Dr. Yambazi Banda to lead the company's scientific team. Mumm brings expertise from founding Deka Biosciences and being a founding member of ARMO BioSciences, which was acquired by Eli Lilly for $1.6 billion in 2018, and will apply patient stratification strategies to neuroimmune conditions like ME/CFS, Long COVID, and POTS. The company aims to address the chronic disease crisis affecting hundreds of millions of patients worldwide through its multi-omic endotyping platform that stratifies patients by disease mechanism before treatment begins.PR NewswireChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted TherapeuticsChronicleBio, a San Francisco-based data-driven biotech company, announced the appointment of Dr. John Mumm as Chief Scientific Officer alongside existing Head of Platform Dr. Yambazi Banda to lead drug development for neuroimmune conditions such as ME/CFS, Long COVID, and POTS. Dr. Mumm brings 30 years of immunology expertise, including founding Deka Biosciences and being a founding member of ARMO BioSciences, which was acquired by Eli Lilly for $1.6 billion in 2018. The company is building a multi-omic endotype framework to stratify patients by disease mechanism before treatment, aiming to address what it describes as a systemic failure to develop effective therapeutics for chronic diseases affecting hundreds of millions of patients worldwide.PR NewswireMerging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditionsChronicleBio, a techbio startup focused on neuroimmune disorders, officially launched in San Francisco on August 5, 2025, with a mission to build an AI-ready data platform for complex chronic conditions including POTS, ME/CFS, and Long COVID. The company was founded by Fidji Simo (current Instacart CEO and incoming OpenAI applications division CEO), Rohit Gupta (formerly of Stanford and UCSF), and Rishi Reddy of Tarsadia Investments, who together aim to address a critical gap in biomedical research affecting nearly 300 million people worldwide. The platform is already operational in multiple clinics in the U.S. and India, integrating multi-omic, clinical, and real-world patient data to accelerate biomarker discovery and precision therapeutic development.PR NewswireSolve M.E., Brain Inflammation Collaborative (BIC), ChronicleBio, Complex Disorders Alliance, and CareEvolution Launch Groundbreaking Partnership to Accelerate Research on ME/CFS, Long Covid, and IACCSolve M.E., the Brain Inflammation Collaborative (BIC), ChronicleBio, the Complex Disorders Alliance, and CareEvolution have launched a partnership to advance research on myalgic encephalomyelitis (ME)/chronic fatigue syndrome, Long Covid, and other infection-associated chronic conditions. The Brain Inflammation Collaborative will take over management of Solve M.E. 's Solve Together patient database platform and expand it to include pediatric populations and additional diagnoses, while ChronicleBio will leverage the data to fuel clinical trials. A full roll-out of the platform under BIC leadership is expected in 2025.